Shionogi in deal with Concordia Pharmaceuticals for its pediatric products

Shionogi Inc. has entered into an agreement with Concordia Pharmaceuticals Inc. (CPI), a wholly owned subsidiary of Concordia Healthcare Inc. Under the agreement CPI will acquire the rights to three Shionogi products, Kapvay™, Orapred ODT® and Orapred® OS, and will get an exclusive license the rights to another product, Ulesfia®. Shionogi will also provide transition services to CPI as part of this agreement.